What is the role of neoadjuvant chemotherapy in the treatment of ovarian cancer?

Updated: Jan 14, 2019
  • Author: Shannon M Grabosch, MD; Chief Editor: from Memorial Sloan-Kettering - Yukio Sonoda, MD  more...
  • Print


While neoadjuvant chemotherapy has been demonstrated as noninferior to primary cytoreductive surgery and could be considered in all patients with advanced disease, it may be of particular benefit in certain subgroups of patients. [14, 15]  Women who are unlikely to achieve optimal up-front surgical debulking due to extensive disease (lung or liver metastasis, disease in the porta hepatis, significant disease in the small bowel mesentery, or massive ascites) or those who are poor candidates to withstand aggressive surgery should be considered for neoadjuvant chemotherapy. [16]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!